Hinge Health CFO sells 55,561 shares in plan

Hinge Health’s chief financial officer completed pre-arranged open‑market stock sales under a Rule 10b5‑1 trading plan.

Rhea-AI Filing Summary

Hinge Health, Inc. (HNGE) reported that Chief Financial Officer James Budge sold a total of 55,561 shares of Class A common stock on September 10, 2026, in multiple open-market transactions at weighted average prices ranging from about $88.22 to $91.62. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by James Budge and his spouse on June 11, 2026.

Insider Trade Summary 10b5-1

Net Seller: 55,561 shares

Net Sell 5 txns

Insider Budge James

Role Chief Financial Officer

Sold 55,561 shs ($4.97M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	13,261	$88.2229	$1.17M
Sale	Class A Common Stock F1, F3	13,807	$89.0028	$1.23M
Sale	Class A Common Stock F1, F4	21,783	$90.048	$1.96M
Sale	Class A Common Stock F1, F5	5,910	$90.762	$536K
Sale	Class A Common Stock F1, F6	800	$91.6175	$73K

Holdings After Transaction: Class A Common Stock — 349,062 shares (Direct)

Footnotes (6)

1. F1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and his spouse on June 11, 2026.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $87.44 and the highest price at which shares were sold was $88.41. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $88.44 and the highest price at which shares were sold was $89.43. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
4. F4. Represents the weighted average sale price. The lowest price at which shares were sold was $89.45 and the highest price at which shares were sold was $90.445. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
5. F5. Represents the weighted average sale price. The lowest price at which shares were sold was $90.45 and the highest price at which shares were sold was $91.42. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
6. F6. Represents the weighted average sale price. The lowest price at which shares were sold was $91.53 and the highest price at which shares were sold was $91.75. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Total shares sold: 55,561 shares Tranche 1 sale: 13,261 shares at $88.2229 per share Tranche 2 sale: 13,807 shares at $89.0028 per share +3 more

6 metrics

Total shares sold 55,561 shares Aggregate Class A common stock sales by the CFO on September 10, 2026

Tranche 1 sale 13,261 shares at $88.2229 per share Weighted average price; individual trades between $87.44 and $88.41

Tranche 2 sale 13,807 shares at $89.0028 per share Weighted average price; individual trades between $88.44 and $89.43

Tranche 3 sale 21,783 shares at $90.0480 per share Weighted average price; individual trades between $89.45 and $90.445

Tranche 4 sale 5,910 shares at $90.7620 per share Weighted average price; individual trades between $90.45 and $91.42

Tranche 5 sale 800 shares at $91.6175 per share Weighted average price; individual trades between $91.53 and $91.75

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price."

Class A Common Stock financial

"security title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HNGE disclose for its Chief Financial Officer?

Hinge Health disclosed that Chief Financial Officer James Budge sold 55,561 shares of Class A common stock on September 10, 2026 in a series of open-market transactions at different weighted average prices.

How many HNGE shares did the CFO sell on September 10, 2026 and at what prices?

On September 10, 2026, the CFO sold 55,561 shares of HNGE Class A common stock in several tranches at weighted average prices between about $88.22 and $91.62, with detailed low and high prices disclosed for each tranche.

Were the HNGE CFO’s stock sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and his spouse on June 11, 2026.

What price range applied to the largest single tranche of HNGE shares sold by the CFO?

The largest tranche of 21,783 shares had a weighted average sale price of $90.0480, with individual trades executed between $89.45 and $90.445 per share.

How does the filing describe the sale prices for the HNGE CFO transactions?

For each tranche, the filing reports a weighted average sale price and discloses that the lowest and highest prices for individual trades within that tranche ranged from $87.44 up to $91.75 per share.

Does the Form 4 state the CFO’s remaining HNGE shareholdings after these sales?

No. The reported transactions list the shares sold and related prices, but the line items do not include a disclosed number of shares held directly after the reported sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 07:38 PM Accepted by SEC EDGAR 09/11/2026 - 07:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Budge James

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CALIFORNIA 94105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/10/2026		S(1)		13,261	D	$88.2229(2)	391,362	D
Class A Common Stock	09/10/2026		S(1)		13,807	D	$89.0028(3)	377,555	D
Class A Common Stock	09/10/2026		S(1)		21,783	D	$90.048(4)	355,772	D
Class A Common Stock	09/10/2026		S(1)		5,910	D	$90.762(5)	349,862	D
Class A Common Stock	09/10/2026		S(1)		800	D	$91.6175(6)	349,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and his spouse on June 11, 2026.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $87.44 and the highest price at which shares were sold was $88.41. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $88.44 and the highest price at which shares were sold was $89.43. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Represents the weighted average sale price. The lowest price at which shares were sold was $89.45 and the highest price at which shares were sold was $90.445. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

5. Represents the weighted average sale price. The lowest price at which shares were sold was $90.45 and the highest price at which shares were sold was $91.42. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

6. Represents the weighted average sale price. The lowest price at which shares were sold was $91.53 and the highest price at which shares were sold was $91.75. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

	/s/ James Budge	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)